Wakefield Group
VC Fund
Charlotte, United States
Wakefield Group is a VC firm that invests in Southeast of the United States.
- Total investments:
- 35
- Last investment:
- Lead investor:
- 31%
Last updated:
For AI agents: llms.txt
Industries Wakefield Group invests in
SoftwareMobileMedicalHealth CareInformation Technology
Stages Wakefield Group invests in
Series ASeries BFunding RoundSeries EPrivate Equity
Countries Wakefield Group invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anna Spangler Nelson
|
|||
David V. Gilroy
|
|||
|
Thomas C. Nelson
|
|||
Investment Focus
Industry
- Software 9 (26%)
- Mobile 5 (14%)
- Medical 5 (14%)
- Health Care 5 (14%)
- Information Technology 5 (14%)
Stage
- Series A 10 (29%)
- Series B 8 (23%)
- Funding Round 8 (23%)
- Series E 2 (6%)
- Private Equity 2 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Anna Spangler Nelson
Partner
|
Partner | Total investments: 1 | Find email | |
|
David V. Gilroy
Partner
|
Partner | Total investments: 0 | Find email | |
|
Thomas C. Nelson
Partner
|
Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Sift Media
|
Sift MediaSift Media is leveraging advanced AI and machine learning algorithms to hyper-target app install ads for its clients. They sift through 50 billion mobile ad requests daily, leveraging advanced AI & machine learning algorithms to hyper-target app install ads for our clients. To date, Sift has served 40B+ mobile ads and delivered 25M+app installs for thousands of advertisers. In January 2016, Sift announced $3.25 million in funding led by Wakefield Group, with participation from Piedmont Capital, Alerion Ventures, IDEA Fund Partners, and several angel investors. | Series A / Jan 14, 2016 | |
Envisia Therapeutics
|
As many as 285 million people suffer from disease-related visual impairments and blindness1, but an estimated 80 percent of these visual impairments are actually preventable2. Unfortunately, the safety and effectiveness of many medical therapies for ocular disorders are limited due to poor drug uptake, non-specificity to target tissues, systemicside effects, or poor adherence to therapy. With a rapidly aging population, the unmet medical needs in ocular disease are becoming even more pronounced. As a result, patients and physicians are seeking improved ocular therapeutics that can significantly enhance patient outcomes and convenience. | $25M / Series A / Nov 12, 2013 | |
rPath
|
rPath helps automate application deployment and maintenance across physical, virtual and cloud environments. rPath's release automation platform is based on a unique version control repository for managing deployed software systems. The result is a complete automation solution for low-overhead and compliant application deployment andmaintenance.The company was founded in 2005 and is headquartered in Raleigh, North Carolina. | $7M / Series D / Oct 22, 2010 | |
|
rPath
|
rPath helps automate application deployment and maintenance across physical, virtual and cloud environments. rPath's release automation platform is based on a unique version control repository for managing deployed software systems. The result is a complete automation solution for low-overhead and compliant application deployment andmaintenance.The company was founded in 2005 and is headquartered in Raleigh, North Carolina. | $10M / Series C / Jun 24, 2008 | |
Appia
|
Appia is the leading mobile user acquisition network; delivering mobile app downloads to over 1 billion users across 200 countries. Its platform was built to best serve the needs of mobile advertisers today, and Appia guarantees more app installs and the highest profit per install for its customers. Appia's robust network and advancedtechnology ensure apps are delivered to the best quality, largest audience possible. Brands like ngmoco, AppBrain, Fiksu, Playtika, Cupid and Zedge trust Appia with their mobile app discovery.Appia's extensive network of publishers and advertisers is constantly developing and its product portfolio continues to evolve, allowing it to bring quality apps to highly engaged consumers. Appia has raised $30M in funding from Venrock, DCM’s A-Fund, Trident Capital, Eric Schmidt’s TomorrowVentures, Relay Ventures, the Social Internet Fund, Noro-Moseley Partners, and Wakefield Group. The Wall Street Journal ranked Appia #22 on its list of the Top 50 Venture Backed Companies in 2012, the second year in a row that Appia has made the WSJ list of the Top 50, known as “The Next Big Thing”. With offices in San Francisco, CA and Durham, NC, as well as global sales offices, Appia has quickly become the largest, non-incentivized network. For additional information, visit appia.com or follow @Appia. | $3.3M / Series A / Jun 01, 2008 | |
FrontStream
|
FrontStream is revolutionizing philanthropy through the use of integrated data that connects causes and organizations with their donors and supporters. The FrontStream Philanthropy Platform is an integrated ecosystem of software and services that unifies fundraising, data analysis, event management, employee giving, volunteering and corporatesocial responsibility (CSR) initiatives. They provide an unparalleled set of tools and data that enables nonprofits and corporations to better understand and enhance the impact of their collective philanthropic efforts. | $16M / Series A / Apr 01, 2008 | |
Liquidia Technologies
|
Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed toimprove the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration. | $16M / Series B / Mar 05, 2007 | |
|
rPath
|
rPath helps automate application deployment and maintenance across physical, virtual and cloud environments. rPath's release automation platform is based on a unique version control repository for managing deployed software systems. The result is a complete automation solution for low-overhead and compliant application deployment andmaintenance.The company was founded in 2005 and is headquartered in Raleigh, North Carolina. | $9.1M / Series B / Jan 24, 2007 | |
Motricity
|
Motricity is Mobile Data and Solutions Provider Motricity Changes Corporate Name to Voltari. Voltari is a digital advertising company dedicated to helping companies get the most out of their marketing budgets and the lifetime value of their customers, built on more than 10 years of experience in the mobile industry. | $32M / Aug 11, 2006 | |
|
Liquidia Technologies
|
Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed toimprove the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration. | $6M / Series A / Jun 14, 2006 | |
| See all 35 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
SaaS Investors
99,274 investors
Enterprise Investors
77,348 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Medical Investors
18,848 investors
Mobile Investors
12,672 investors
SaaS VC Funds
61,208 investors
Enterprise VC Funds
49,693 investors
Software VC Funds
31,919 investors
FAQ
What does Wakefield Group invest in?
Wakefield Group invests primarily in Software, Mobile and Medical startups, most often at Series A and Series B stage. Most of the 35 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Wakefield Group?
Public channels for Wakefield Group include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Wakefield Group?
The team at Wakefield Group includes Anna Spangler Nelson (Partner), David V. Gilroy (Partner) and Thomas C. Nelson (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
